Sunesis Pharmaceuticals Hits New 1-Year High at $7.71 (SNSS)
Sunesis Pharmaceuticals (NASDAQ:SNSS)’s share price hit a new 52-week high during trading on Monday , AnalystRatings.NET reports. The company traded as high as $7.71 and last traded at $7.64, with a volume of 782,084 shares trading hands. The stock had previously closed at $7.33.
The stock’s 50-day moving average is $6.47 and its 200-day moving average is $5.85. The company’s market cap is $458.5 million.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.20) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.17) by $0.03. The company had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.32 million. During the same quarter last year, the company posted $0.18 earnings per share. Sunesis Pharmaceuticals’s revenue was up .0% compared to the same quarter last year. Analysts expect that Sunesis Pharmaceuticals will post $-0.74 EPS for the current fiscal year.
In other Sunesis Pharmaceuticals news, Director Dayton Misfeldt unloaded 743,700 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $6.64, for a total value of $4,938,168.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.